Company
Headquarters: Taichung, Taiwan
Employees: 579
CEO: Mr. Chi-Hsien Chan
TW$11.76 Billion
TWD as of July 1, 2024
US$361.3 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, an influenza vaccine; tetanus toxoid alum precipitated products used for prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent and Tetravalent influenza vaccines; Influenza A (H1N1) virus monovalent vaccines; and Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is based in Taichung City, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Adimmune Corp has the following listings and related stock indices.
Stock: TWSE: 4142 wb_incandescent